Literature DB >> 2831687

Stereotaxic fine needle aspiration cytology of clinically occult malignant and premalignant breast lesions.

M Bibbo1, M Scheiber, R Cajulis, C M Keebler, G L Wied, K Dowlatshahi.   

Abstract

Stereotaxic fine needle aspiration (FNA) cytology was used to study clinically occult (nonpalpable) breast lesions in 114 consecutive patients with mammographically suspicious findings prior to excisional biopsy. The aspirate contained insufficient material for cytologic evaluation in 15 cases (13.2%), which were histologically diagnosed as benign (7 cases), atypical hyperplasia (7 cases) or carcinoma in situ (1 case). The cytologic findings indicated a benign lesion in 77 cases (67.5%), which were histologically diagnosed as benign (71 cases) or atypical ductal hyperplasia (6 cases). The cytologic sample showed atypia in eight cases (7.0%), which were histologically diagnosed as severe atypical ductal hyperplasia (three cases), carcinoma in situ (one case) or proliferative fibrocystic disease (four cases). In the eight cases (7.0%) cytologically interpreted as probably malignant, histology confirmed six invasive carcinomas, one carcinoma in situ and one fibrocystic disease. Of six cases (4.4%) cytologically reported as malignant, five were histologically diagnosed as invasive carcinoma and one as carcinoma in situ. Overall, stereotaxic FNA cytology reported as malignant or probably malignant 14 of the 15 cases with a histologic confirmation of malignancy, for a sensitivity of 93.3%. Cytology correctly identified 78 of the 83 histologically negative cases, for a specificity of 94.0%. The 16 cases histologically diagnosed as ductal hyperplasia, which carries a high risk for subsequent malignancy, were studied in detail in an effort to define histologic and cytologic criteria for this entity. Using selected histologic criteria, 11 of these cases were graded as showing mild-to-moderate atypical hyperplasia and 5 as showing severe atypical hyperplasia. Three of the latter cases were similarly identified by an analogous cytologic grading; the other two cases had insufficient cytologic samples. The total results in this series of 114 cases support the use of stereotaxic FNA cytology in the diagnosis of these nonpalpable breast lesions, examples of which are illustrated. In particular, it may help to raise the low specificity yielded by mammography alone, which would represent a significant advance for the patient in terms of the accuracy, expediency and reduced cost of diagnosing these lesions.

Entities:  

Mesh:

Year:  1988        PMID: 2831687

Source DB:  PubMed          Journal:  Acta Cytol        ISSN: 0001-5547            Impact factor:   2.319


  6 in total

Review 1.  Percutaneous biopsies of the breast: state of the art.

Authors:  B D Fornage
Journal:  Cardiovasc Intervent Radiol       Date:  1991 Jan-Feb       Impact factor: 2.740

2.  A case of solitary intraductal papilloma of the breast coexisting with ductal carcinoma in situ (DCIS).

Authors:  Nobuyuki Takemoto; Hiroshi Yamamoto; Katsuko Shiraishi; Junko Koike
Journal:  J Med Ultrason (2001)       Date:  2007-03-15       Impact factor: 1.314

3.  Association of breast cancer with the finding of atypical ductal hyperplasia at core breast biopsy.

Authors:  M M Moore; C W Hargett; J B Hanks; L L Fajardo; J A Harvey; H F Frierson; C L Slingluff
Journal:  Ann Surg       Date:  1997-06       Impact factor: 12.969

Review 4.  Breast cancer: early diagnosis of precursor lesions and clinically inapparent carcinoma by fine needle aspiration.

Authors:  J A Linsk
Journal:  Med Oncol Tumor Pharmacother       Date:  1991

5.  Myoepithelial cells: any role in aspiration cytology smears of breast tumors?

Authors:  Sanjib Kumar Pattari; Pranab Dey; Subhash K Gupta; Kusum Joshi
Journal:  Cytojournal       Date:  2008-04-21       Impact factor: 2.091

6.  Efficacy of Modified Masood Scoring System (MMSS) in Cytological Diagnosis of Breast Lesions.

Authors:  Justina William; Kanwal Masih; Uma Pradhan; Jasneet Kaur; Upinder Singh; Gulshanjit Singh
Journal:  Cureus       Date:  2022-02-16
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.